Calidi Biotherapeutics, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 7.23 million compared to USD 6.46 million a year ago. Basic loss per share from continuing operations was USD 0.2 compared to USD 0.75 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.75 USD | +10.55% |
|
+7.96% | -88.41% |
07-08 | Calidi Biotherapeutics, Inc. Enters into A Certain Loan Agreement with Dennis R. Conklin | CI |
07-05 | Calidi Biotherapeutics to Implement 1-For-10 Reverse Stock Split | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-88.41% | 11.23M | |
+20.63% | 127B | |
+25.04% | 27.67B | |
-20.17% | 20.33B | |
-17.17% | 16.79B | |
-18.07% | 15.63B | |
-47.70% | 14.65B | |
+11.92% | 14.84B | |
+58.32% | 14.43B | |
+149.98% | 12.49B |
- Stock Market
- Equities
- CLDI Stock
- News CALI BIOTPAR
- Calidi Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024